LHC Group, Inc.
LHC Group, Inc. (LHCG) Stock Competitors & Peer Comparison
See (LHCG) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LHCG | $169.81 | +0.00% | 5.3B | 82.83 | $2.05 | N/A |
| HCA | $391.51 | -0.27% | 87.4B | 13.57 | $29.04 | +0.75% |
| THC | $175.12 | -1.62% | 15B | 9.03 | $19.24 | N/A |
| SOLV | $75.78 | -1.26% | 13.3B | 9.40 | $8.17 | N/A |
| DVA | $197.19 | -0.74% | 12.7B | 19.13 | $10.38 | N/A |
| FMS | $21.63 | -0.02% | 11.7B | 11.39 | $1.90 | +4.03% |
| EHC | $104.72 | +0.26% | 10.4B | 17.97 | $5.84 | +0.71% |
| ENSG | $171.05 | -0.36% | 10B | 28.00 | $6.14 | +0.15% |
| UHS | $156.60 | -3.60% | 9.9B | 6.59 | $23.95 | +0.51% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
Stock Comparison
LHCG vs HCA Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, HCA has a market cap of 87.4B. Regarding current trading prices, LHCG is priced at $169.81, while HCA trades at $391.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas HCA's P/E ratio is 13.57. In terms of profitability, LHCG's ROE is +0.04%, compared to HCA's ROE of -1.23%. Regarding short-term risk, LHCG is less volatile compared to HCA. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check HCA's competition here
LHCG vs THC Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, THC has a market cap of 15B. Regarding current trading prices, LHCG is priced at $169.81, while THC trades at $175.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas THC's P/E ratio is 9.03. In terms of profitability, LHCG's ROE is +0.04%, compared to THC's ROE of +0.41%. Regarding short-term risk, LHCG is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check THC's competition here
LHCG vs SOLV Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, SOLV has a market cap of 13.3B. Regarding current trading prices, LHCG is priced at $169.81, while SOLV trades at $75.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas SOLV's P/E ratio is 9.40. In terms of profitability, LHCG's ROE is +0.04%, compared to SOLV's ROE of +0.31%. Regarding short-term risk, LHCG is less volatile compared to SOLV. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check SOLV's competition here
LHCG vs DVA Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, DVA has a market cap of 12.7B. Regarding current trading prices, LHCG is priced at $169.81, while DVA trades at $197.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas DVA's P/E ratio is 19.13. In terms of profitability, LHCG's ROE is +0.04%, compared to DVA's ROE of -1.33%. Regarding short-term risk, LHCG is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check DVA's competition here
LHCG vs FMS Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, FMS has a market cap of 11.7B. Regarding current trading prices, LHCG is priced at $169.81, while FMS trades at $21.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas FMS's P/E ratio is 11.39. In terms of profitability, LHCG's ROE is +0.04%, compared to FMS's ROE of +0.07%. Regarding short-term risk, LHCG is less volatile compared to FMS. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check FMS's competition here
LHCG vs EHC Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, EHC has a market cap of 10.4B. Regarding current trading prices, LHCG is priced at $169.81, while EHC trades at $104.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas EHC's P/E ratio is 17.97. In terms of profitability, LHCG's ROE is +0.04%, compared to EHC's ROE of +0.25%. Regarding short-term risk, LHCG is less volatile compared to EHC. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check EHC's competition here
LHCG vs ENSG Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, ENSG has a market cap of 10B. Regarding current trading prices, LHCG is priced at $169.81, while ENSG trades at $171.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas ENSG's P/E ratio is 28.00. In terms of profitability, LHCG's ROE is +0.04%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, LHCG is less volatile compared to ENSG. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check ENSG's competition here
LHCG vs UHS Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, UHS has a market cap of 9.9B. Regarding current trading prices, LHCG is priced at $169.81, while UHS trades at $156.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas UHS's P/E ratio is 6.59. In terms of profitability, LHCG's ROE is +0.04%, compared to UHS's ROE of +0.21%. Regarding short-term risk, LHCG is less volatile compared to UHS. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check UHS's competition here
LHCG vs OSH Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, LHCG is priced at $169.81, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas OSH's P/E ratio is -17.65. In terms of profitability, LHCG's ROE is +0.04%, compared to OSH's ROE of +4.64%. Regarding short-term risk, LHCG is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check OSH's competition here
LHCG vs CHE Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, CHE has a market cap of 5.8B. Regarding current trading prices, LHCG is priced at $169.81, while CHE trades at $437.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas CHE's P/E ratio is 23.98. In terms of profitability, LHCG's ROE is +0.04%, compared to CHE's ROE of +0.25%. Regarding short-term risk, LHCG is less volatile compared to CHE. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check CHE's competition here
LHCG vs MMED Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, MMED has a market cap of 3.3B. Regarding current trading prices, LHCG is priced at $169.81, while MMED trades at $11.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas MMED's P/E ratio is -9.35. In terms of profitability, LHCG's ROE is +0.04%, compared to MMED's ROE of -0.09%. Regarding short-term risk, LHCG is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check MMED's competition here
LHCG vs AMED Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, LHCG is priced at $169.81, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas AMED's P/E ratio is 39.30. In terms of profitability, LHCG's ROE is +0.04%, compared to AMED's ROE of +0.09%. Regarding short-term risk, LHCG is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check AMED's competition here
LHCG vs OPCH Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, OPCH has a market cap of 3.3B. Regarding current trading prices, LHCG is priced at $169.81, while OPCH trades at $21.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas OPCH's P/E ratio is 16.35. In terms of profitability, LHCG's ROE is +0.04%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, LHCG is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check OPCH's competition here
LHCG vs BKD Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, BKD has a market cap of 3.2B. Regarding current trading prices, LHCG is priced at $169.81, while BKD trades at $13.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas BKD's P/E ratio is -15.29. In terms of profitability, LHCG's ROE is +0.04%, compared to BKD's ROE of +401.19%. Regarding short-term risk, LHCG is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check BKD's competition here
LHCG vs NHC Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, NHC has a market cap of 3.1B. Regarding current trading prices, LHCG is priced at $169.81, while NHC trades at $188.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas NHC's P/E ratio is 24.87. In terms of profitability, LHCG's ROE is +0.04%, compared to NHC's ROE of +0.12%. Regarding short-term risk, LHCG is less volatile compared to NHC. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check NHC's competition here
LHCG vs LFST Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, LFST has a market cap of 2.9B. Regarding current trading prices, LHCG is priced at $169.81, while LFST trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas LFST's P/E ratio is 123.17. In terms of profitability, LHCG's ROE is +0.04%, compared to LFST's ROE of +0.02%. Regarding short-term risk, LHCG is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check LFST's competition here
LHCG vs ACHC Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, ACHC has a market cap of 2.1B. Regarding current trading prices, LHCG is priced at $169.81, while ACHC trades at $23.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas ACHC's P/E ratio is -1.90. In terms of profitability, LHCG's ROE is +0.04%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, LHCG is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check ACHC's competition here
LHCG vs SEM Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, LHCG is priced at $169.81, while SEM trades at $16.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas SEM's P/E ratio is 15.44. In terms of profitability, LHCG's ROE is +0.04%, compared to SEM's ROE of +0.08%. Regarding short-term risk, LHCG is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check SEM's competition here
LHCG vs ASTH Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, ASTH has a market cap of 1.9B. Regarding current trading prices, LHCG is priced at $169.81, while ASTH trades at $38.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas ASTH's P/E ratio is 62.05. In terms of profitability, LHCG's ROE is +0.04%, compared to ASTH's ROE of +0.04%. Regarding short-term risk, LHCG is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check ASTH's competition here
LHCG vs AMEH Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, LHCG is priced at $169.81, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas AMEH's P/E ratio is 39.25. In terms of profitability, LHCG's ROE is +0.04%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, LHCG is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check AMEH's competition here
LHCG vs SGRY Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, SGRY has a market cap of 1.8B. Regarding current trading prices, LHCG is priced at $169.81, while SGRY trades at $13.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas SGRY's P/E ratio is -22.71. In terms of profitability, LHCG's ROE is +0.04%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, LHCG is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check SGRY's competition here
LHCG vs MD Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, MD has a market cap of 1.7B. Regarding current trading prices, LHCG is priced at $169.81, while MD trades at $21.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas MD's P/E ratio is 10.33. In terms of profitability, LHCG's ROE is +0.04%, compared to MD's ROE of +0.20%. Regarding short-term risk, LHCG is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check MD's competition here
LHCG vs ADUS Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, ADUS has a market cap of 1.7B. Regarding current trading prices, LHCG is priced at $169.81, while ADUS trades at $92.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas ADUS's P/E ratio is 17.09. In terms of profitability, LHCG's ROE is +0.04%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, LHCG is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check ADUS's competition here
LHCG vs AVAH Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, AVAH has a market cap of 1.6B. Regarding current trading prices, LHCG is priced at $169.81, while AVAH trades at $7.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas AVAH's P/E ratio is 6.06. In terms of profitability, LHCG's ROE is +0.04%, compared to AVAH's ROE of +2.41%. Regarding short-term risk, LHCG is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check AVAH's competition here
LHCG vs AGL Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, AGL has a market cap of 1.4B. Regarding current trading prices, LHCG is priced at $169.81, while AGL trades at $82.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas AGL's P/E ratio is -3.82. In terms of profitability, LHCG's ROE is +0.04%, compared to AGL's ROE of -1.46%. Regarding short-term risk, LHCG is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check AGL's competition here
LHCG vs HCSG Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, HCSG has a market cap of 1.4B. Regarding current trading prices, LHCG is priced at $169.81, while HCSG trades at $20.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas HCSG's P/E ratio is 21.51. In terms of profitability, LHCG's ROE is +0.04%, compared to HCSG's ROE of +0.14%. Regarding short-term risk, LHCG is less volatile compared to HCSG. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check HCSG's competition here
LHCG vs ARDT Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, ARDT has a market cap of 1.3B. Regarding current trading prices, LHCG is priced at $169.81, while ARDT trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas ARDT's P/E ratio is 9.72. In terms of profitability, LHCG's ROE is +0.04%, compared to ARDT's ROE of +0.09%. Regarding short-term risk, LHCG is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check ARDT's competition here
LHCG vs BKDT Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, LHCG is priced at $169.81, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas BKDT's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to BKDT's ROE of +401.19%. Regarding short-term risk, LHCG is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check BKDT's competition here
LHCG vs PNTG Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, PNTG has a market cap of 1.2B. Regarding current trading prices, LHCG is priced at $169.81, while PNTG trades at $33.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas PNTG's P/E ratio is 39.44. In terms of profitability, LHCG's ROE is +0.04%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, LHCG is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check PNTG's competition here
LHCG vs CMPS Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, CMPS has a market cap of 1.1B. Regarding current trading prices, LHCG is priced at $169.81, while CMPS trades at $12.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas CMPS's P/E ratio is -3.76. In terms of profitability, LHCG's ROE is +0.04%, compared to CMPS's ROE of -1.51%. Regarding short-term risk, LHCG is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check CMPS's competition here
LHCG vs AMN Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, AMN has a market cap of 1.1B. Regarding current trading prices, LHCG is priced at $169.81, while AMN trades at $27.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas AMN's P/E ratio is -32.16. In terms of profitability, LHCG's ROE is +0.04%, compared to AMN's ROE of -0.05%. Regarding short-term risk, LHCG is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check AMN's competition here
LHCG vs INNV Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, INNV has a market cap of 977.3M. Regarding current trading prices, LHCG is priced at $169.81, while INNV trades at $7.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas INNV's P/E ratio is -90.00. In terms of profitability, LHCG's ROE is +0.04%, compared to INNV's ROE of -0.09%. Regarding short-term risk, LHCG is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check INNV's competition here
LHCG vs USPH Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, USPH has a market cap of 943M. Regarding current trading prices, LHCG is priced at $169.81, while USPH trades at $61.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas USPH's P/E ratio is 123.92. In terms of profitability, LHCG's ROE is +0.04%, compared to USPH's ROE of +0.00%. Regarding short-term risk, LHCG is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check USPH's competition here
LHCG vs TALK Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, TALK has a market cap of 871.1M. Regarding current trading prices, LHCG is priced at $169.81, while TALK trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas TALK's P/E ratio is 130.00. In terms of profitability, LHCG's ROE is +0.04%, compared to TALK's ROE of +0.01%. Regarding short-term risk, LHCG and TALK have similar daily volatility (0.39).Check TALK's competition here
LHCG vs FSHCX Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, FSHCX has a market cap of 820.5M. Regarding current trading prices, LHCG is priced at $169.81, while FSHCX trades at $107.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas FSHCX's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to FSHCX's ROE of N/A. Regarding short-term risk, LHCG is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check FSHCX's competition here
LHCG vs SNDA Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, SNDA has a market cap of 740.2M. Regarding current trading prices, LHCG is priced at $169.81, while SNDA trades at $37.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas SNDA's P/E ratio is -6.34. In terms of profitability, LHCG's ROE is +0.04%, compared to SNDA's ROE of -0.35%. Regarding short-term risk, LHCG is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check SNDA's competition here
LHCG vs EHAB Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, LHCG is priced at $169.81, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas EHAB's P/E ratio is -197.14. In terms of profitability, LHCG's ROE is +0.04%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, LHCG is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check EHAB's competition here
LHCG vs GMRS Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, GMRS has a market cap of 501.9M. Regarding current trading prices, LHCG is priced at $169.81, while GMRS trades at $11.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas GMRS's P/E ratio is 68.81. In terms of profitability, LHCG's ROE is +0.04%, compared to GMRS's ROE of N/A. Regarding short-term risk, LHCG is less volatile compared to GMRS. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check GMRS's competition here
LHCG vs TOI Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, TOI has a market cap of 458.9M. Regarding current trading prices, LHCG is priced at $169.81, while TOI trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas TOI's P/E ratio is -13.11. In terms of profitability, LHCG's ROE is +0.04%, compared to TOI's ROE of +3.27%. Regarding short-term risk, LHCG is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check TOI's competition here
LHCG vs MCTA Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, LHCG is priced at $169.81, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas MCTA's P/E ratio is 419.36. In terms of profitability, LHCG's ROE is +0.04%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, LHCG is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check MCTA's competition here
LHCG vs CCRN Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, CCRN has a market cap of 421.9M. Regarding current trading prices, LHCG is priced at $169.81, while CCRN trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas CCRN's P/E ratio is -4.28. In terms of profitability, LHCG's ROE is +0.04%, compared to CCRN's ROE of -0.27%. Regarding short-term risk, LHCG is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check CCRN's competition here
LHCG vs CYH Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, CYH has a market cap of 394.6M. Regarding current trading prices, LHCG is priced at $169.81, while CYH trades at $2.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas CYH's P/E ratio is 0.81. In terms of profitability, LHCG's ROE is +0.04%, compared to CYH's ROE of +0.06%. Regarding short-term risk, LHCG is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check CYH's competition here
LHCG vs AIRS Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, AIRS has a market cap of 376M. Regarding current trading prices, LHCG is priced at $169.81, while AIRS trades at $5.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas AIRS's P/E ratio is -31.35. In terms of profitability, LHCG's ROE is +0.04%, compared to AIRS's ROE of -0.12%. Regarding short-term risk, LHCG is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check AIRS's competition here
LHCG vs AONC Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, AONC has a market cap of 351M. Regarding current trading prices, LHCG is priced at $169.81, while AONC trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas AONC's P/E ratio is -13.48. In terms of profitability, LHCG's ROE is +0.04%, compared to AONC's ROE of +0.06%. Regarding short-term risk, LHCG is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check AONC's competition here
LHCG vs AUNA Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, AUNA has a market cap of 319M. Regarding current trading prices, LHCG is priced at $169.81, while AUNA trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas AUNA's P/E ratio is 15.96. In terms of profitability, LHCG's ROE is +0.04%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, LHCG is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check AUNA's competition here
LHCG vs CSU Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, LHCG is priced at $169.81, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas CSU's P/E ratio is 0.67. In terms of profitability, LHCG's ROE is +0.04%, compared to CSU's ROE of -0.51%. Regarding short-term risk, LHCG is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check CSU's competition here
LHCG vs JYNT Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, JYNT has a market cap of 127.6M. Regarding current trading prices, LHCG is priced at $169.81, while JYNT trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas JYNT's P/E ratio is 99.44. In terms of profitability, LHCG's ROE is +0.04%, compared to JYNT's ROE of +0.17%. Regarding short-term risk, LHCG is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check JYNT's competition here
LHCG vs NAKAW Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, LHCG is priced at $169.81, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas NAKAW's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to NAKAW's ROE of -0.85%. Regarding short-term risk, LHCG is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check NAKAW's competition here
LHCG vs FVE Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, LHCG is priced at $169.81, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas FVE's P/E ratio is -5.64. In terms of profitability, LHCG's ROE is +0.04%, compared to FVE's ROE of -0.15%. Regarding short-term risk, LHCG is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check FVE's competition here
LHCG vs KDLYW Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, LHCG is priced at $169.81, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas KDLYW's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to KDLYW's ROE of -0.85%. Regarding short-term risk, LHCG is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check KDLYW's competition here
LHCG vs BTMD Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, BTMD has a market cap of 87.8M. Regarding current trading prices, LHCG is priced at $169.81, while BTMD trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas BTMD's P/E ratio is 4.63. In terms of profitability, LHCG's ROE is +0.04%, compared to BTMD's ROE of -0.23%. Regarding short-term risk, LHCG is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check BTMD's competition here
LHCG vs DCGO Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, DCGO has a market cap of 62.3M. Regarding current trading prices, LHCG is priced at $169.81, while DCGO trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas DCGO's P/E ratio is -0.33. In terms of profitability, LHCG's ROE is +0.04%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, LHCG is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check DCGO's competition here
LHCG vs ALR Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, LHCG is priced at $169.81, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas ALR's P/E ratio is -1.11. In terms of profitability, LHCG's ROE is +0.04%, compared to ALR's ROE of -0.15%. Regarding short-term risk, LHCG is less volatile compared to ALR. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check ALR's competition here
LHCG vs PIII Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, PIII has a market cap of 43.5M. Regarding current trading prices, LHCG is priced at $169.81, while PIII trades at $12.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas PIII's P/E ratio is -0.34. In terms of profitability, LHCG's ROE is +0.04%, compared to PIII's ROE of +1.85%. Regarding short-term risk, LHCG is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check PIII's competition here
LHCG vs IMAC Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, LHCG is priced at $169.81, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas IMAC's P/E ratio is -2.27. In terms of profitability, LHCG's ROE is +0.04%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, LHCG is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check IMAC's competition here
LHCG vs CCEL Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, CCEL has a market cap of 27.9M. Regarding current trading prices, LHCG is priced at $169.81, while CCEL trades at $3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas CCEL's P/E ratio is -10.81. In terms of profitability, LHCG's ROE is +0.04%, compared to CCEL's ROE of +0.16%. Regarding short-term risk, LHCG is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check CCEL's competition here
LHCG vs CANO-WT Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, LHCG is priced at $169.81, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, LHCG is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check CANO-WT's competition here
LHCG vs AIH Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, LHCG is priced at $169.81, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas AIH's P/E ratio is -2.78. In terms of profitability, LHCG's ROE is +0.04%, compared to AIH's ROE of +1.16%. Regarding short-term risk, LHCG is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check AIH's competition here
LHCG vs CANO Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, LHCG is priced at $169.81, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas CANO's P/E ratio is -0.01. In terms of profitability, LHCG's ROE is +0.04%, compared to CANO's ROE of -1.49%. Regarding short-term risk, LHCG is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check CANO's competition here
LHCG vs FTRP Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, LHCG is priced at $169.81, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas FTRP's P/E ratio is -1.22. In terms of profitability, LHCG's ROE is +0.04%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, LHCG is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check FTRP's competition here
LHCG vs AMS Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, AMS has a market cap of 8.9M. Regarding current trading prices, LHCG is priced at $169.81, while AMS trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas AMS's P/E ratio is -6.14. In terms of profitability, LHCG's ROE is +0.04%, compared to AMS's ROE of -0.06%. Regarding short-term risk, LHCG is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check AMS's competition here
LHCG vs MODV Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, LHCG is priced at $169.81, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas MODV's P/E ratio is -0.03. In terms of profitability, LHCG's ROE is +0.04%, compared to MODV's ROE of +1.84%. Regarding short-term risk, LHCG is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check MODV's competition here
LHCG vs SYRA Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, SYRA has a market cap of 5.6M. Regarding current trading prices, LHCG is priced at $169.81, while SYRA trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas SYRA's P/E ratio is -24.65. In terms of profitability, LHCG's ROE is +0.04%, compared to SYRA's ROE of -0.08%. Regarding short-term risk, LHCG is less volatile compared to SYRA. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check SYRA's competition here
LHCG vs GBNH Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, LHCG is priced at $169.81, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas GBNH's P/E ratio is -0.06. In terms of profitability, LHCG's ROE is +0.04%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, LHCG is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check GBNH's competition here
LHCG vs RHE-PA Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, LHCG is priced at $169.81, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, LHCG's ROE is +0.04%, compared to RHE-PA's ROE of +2.11%. Regarding short-term risk, LHCG is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check RHE-PA's competition here
LHCG vs RHE Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, LHCG is priced at $169.81, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas RHE's P/E ratio is -1.79. In terms of profitability, LHCG's ROE is +0.04%, compared to RHE's ROE of -0.36%. Regarding short-term risk, LHCG is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check RHE's competition here
LHCG vs TOIIW Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, TOIIW has a market cap of 4.2M. Regarding current trading prices, LHCG is priced at $169.81, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas TOIIW's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to TOIIW's ROE of +3.27%. Regarding short-term risk, LHCG is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check TOIIW's competition here
LHCG vs ATIP Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, LHCG is priced at $169.81, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas ATIP's P/E ratio is -0.03. In terms of profitability, LHCG's ROE is +0.04%, compared to ATIP's ROE of +2.05%. Regarding short-term risk, LHCG is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check ATIP's competition here
LHCG vs IMACW Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, LHCG is priced at $169.81, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas IMACW's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, LHCG is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check IMACW's competition here
LHCG vs MNDR Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, MNDR has a market cap of 761K. Regarding current trading prices, LHCG is priced at $169.81, while MNDR trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas MNDR's P/E ratio is -0.36. In terms of profitability, LHCG's ROE is +0.04%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, LHCG is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check MNDR's competition here
LHCG vs CCM Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, CCM has a market cap of 715K. Regarding current trading prices, LHCG is priced at $169.81, while CCM trades at $4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas CCM's P/E ratio is -1.57. In terms of profitability, LHCG's ROE is +0.04%, compared to CCM's ROE of +0.07%. Regarding short-term risk, LHCG is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check CCM's competition here
LHCG vs NIVF Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, NIVF has a market cap of 579.8K. Regarding current trading prices, LHCG is priced at $169.81, while NIVF trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas NIVF's P/E ratio is 0.03. In terms of profitability, LHCG's ROE is +0.04%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, LHCG is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check NIVF's competition here
LHCG vs TALKW Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, TALKW has a market cap of 385.3K. Regarding current trading prices, LHCG is priced at $169.81, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas TALKW's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to TALKW's ROE of +0.01%. Regarding short-term risk, LHCG is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check TALKW's competition here
LHCG vs BACK Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, BACK has a market cap of 174.1K. Regarding current trading prices, LHCG is priced at $169.81, while BACK trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas BACK's P/E ratio is -0.02. In terms of profitability, LHCG's ROE is +0.04%, compared to BACK's ROE of +1.05%. Regarding short-term risk, LHCG is less volatile compared to BACK. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check BACK's competition here
LHCG vs NIVFW Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, NIVFW has a market cap of 90.7K. Regarding current trading prices, LHCG is priced at $169.81, while NIVFW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas NIVFW's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, LHCG is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check NIVFW's competition here
LHCG vs PIIIW Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, PIIIW has a market cap of 87.8K. Regarding current trading prices, LHCG is priced at $169.81, while PIIIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas PIIIW's P/E ratio is -0.02. In terms of profitability, LHCG's ROE is +0.04%, compared to PIIIW's ROE of +1.85%. Regarding short-term risk, LHCG is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check PIIIW's competition here
LHCG vs NVOS Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, NVOS has a market cap of 69.1K. Regarding current trading prices, LHCG is priced at $169.81, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas NVOS's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, LHCG is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check NVOS's competition here
LHCG vs IONM Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, IONM has a market cap of 1.6K. Regarding current trading prices, LHCG is priced at $169.81, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas IONM's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to IONM's ROE of +5.28%. Regarding short-term risk, LHCG is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check IONM's competition here
LHCG vs TLMDW Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, LHCG is priced at $169.81, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas TLMDW's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, LHCG is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check TLMDW's competition here
LHCG vs ATIP-WT Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, LHCG is priced at $169.81, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, LHCG is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check ATIP-WT's competition here
LHCG vs TLMD Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, LHCG is priced at $169.81, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas TLMD's P/E ratio is -1.60. In terms of profitability, LHCG's ROE is +0.04%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, LHCG is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check TLMD's competition here
LHCG vs HNGR Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, LHCG is priced at $169.81, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas HNGR's P/E ratio is 19.71. In terms of profitability, LHCG's ROE is +0.04%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, LHCG is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check HNGR's competition here
LHCG vs AFAM Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, LHCG is priced at $169.81, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas AFAM's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, LHCG is less volatile compared to AFAM. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check AFAM's competition here
LHCG vs TVTY Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, LHCG is priced at $169.81, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas TVTY's P/E ratio is 19.06. In terms of profitability, LHCG's ROE is +0.04%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, LHCG is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check TVTY's competition here
LHCG vs SLHG Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, LHCG is priced at $169.81, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas SLHG's P/E ratio is -1.48. In terms of profitability, LHCG's ROE is +0.04%, compared to SLHG's ROE of N/A. Regarding short-term risk, LHCG is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check SLHG's competition here
LHCG vs SLHGP Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, LHCG is priced at $169.81, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, LHCG's ROE is +0.04%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, LHCG is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check SLHGP's competition here
LHCG vs NFH Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, NFH has a market cap of 0. Regarding current trading prices, LHCG is priced at $169.81, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas NFH's P/E ratio is -19.75. In terms of profitability, LHCG's ROE is +0.04%, compared to NFH's ROE of -0.06%. Regarding short-term risk, LHCG is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for LHCG.Check NFH's competition here
LHCG vs DCGOW Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, LHCG is priced at $169.81, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas DCGOW's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, LHCG is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check DCGOW's competition here
LHCG vs KND Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, KND has a market cap of 0. Regarding current trading prices, LHCG is priced at $169.81, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas KND's P/E ratio is N/A. In terms of profitability, LHCG's ROE is +0.04%, compared to KND's ROE of -0.53%. Regarding short-term risk, LHCG is less volatile compared to KND. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check KND's competition here
LHCG vs DVCR Comparison May 2026
LHCG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LHCG stands at 5.3B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, LHCG is priced at $169.81, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LHCG currently has a P/E ratio of 82.83, whereas DVCR's P/E ratio is 28.34. In terms of profitability, LHCG's ROE is +0.04%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, LHCG is less volatile compared to DVCR. This indicates potentially lower risk in terms of short-term price fluctuations for LHCG.Check DVCR's competition here